PBK在前列腺癌组织中的表达及临床意义

doi:10.3969/j.issn.1000-8535.2017.04.001

广州医药 ›› 2017, Vol. 48 ›› Issue (4): 1-6.DOI: 10.3969/j.issn.1000-8535.2017.04.001

• 论著 • 下一篇

PBK在前列腺癌组织中的表达及临床意义

陈佳鸿¹, 方树敏¹, 梁应科², 刘泽贞², 朱学进², 蔡周达², 董卫民², 钟惟德²

1 惠州市中心人民医院泌尿外科(惠州 516001)
2 广州医科大学附属广州市第一人民医院广东省临床分子医学及分子诊断重点实验室(广州 510180)

收稿日期:2017-03-20 发布日期:2021-12-01
通讯作者: 钟惟德,E-mail:wdezhong@21cn.com
基金资助:
广东省医学科研技术研究基金项目(A2016525)

Expression and clinical significance of PBK in prostate cancer tissues

CHEN Jiahong¹, FANG Shumin¹, LIANG Yingke², LIU Zezhen², ZHU Xuejin², CAI Zhouda², DONG Weimin², ZHONG Weide²

1 Department of Urology, Huizhou Municipal Central Hospital, Huizhou 516001, China
2 Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou FirstPeople's Hospital, Guangzhou Medical University, Guangzhou 510180, China

Received:2017-03-20 Published:2021-12-01

摘要/Abstract

摘要： 目的分析PBK在前列腺癌中的表达及临床意义。方法利用前列腺癌的组织芯片,包含98例前列腺癌及81例对照癌旁组织作为研究对象,免疫组化方法检测PBK的表达情况,并运用统计学方法分析免疫组化芯片及Taylor数据库中PBK表达与前列腺癌临床病理特征之间的关系。结果 PBK在前列腺癌中表达明显升高(P=0.001);且在Gleason高评分组的表达比低评分组表达升高(P=0.001)。Taylor数据库得到相似结果,且运用Kaplan-Meier分析发现PBK与无生化复发生存率显著相关(P=0.007),最后采用Cox回归模型进行多因素综合分析发现在影响前列腺癌预后的队列中,PBK高表达(P=0.041)与Gleason评分、病理分期都是前列腺癌生化复发的独立预测指标。结论 PBK的表达与前列腺癌密切相关,可作为临床诊断及治疗的分子标志物。

关键词: 前列腺癌, PBK, 生化复发

Abstract: Objective To investigate the expression and clinical significance of PBK in prostate cancer. Methods Using tissue microarrays of prostate cancer, which including 98 cases of prostate cancer and 81 cases of normal tissue adjacent to cancer as the research object, the expression of PBK was detected by immunohistochemistry, and statistical analysis was used to analyze the relationship between the expression of PBK and the clinicopathological features of prostate cancer in the microarray and Taylor database. Results The expression of PBK in prostate cancer was significantly higher (P=0.001), and the expression increased in the group of high Gleason score (P=0.001). The Taylor database obtained similar results, and Kaplan-Meier analysis showed that PBK was significantly correlated with the biochemical recurrence free survival (P=0.007). Finally, Cox regression model was used to analyze the prognostic factors of prostate cancer. Result shows that, the high expression of PBK (P=0.041), Gleason score and pathological stage were independent predictors of biochemical recurrence of prostate cancer. Conclusion The expression of PBK is closely related to prostate cancer, and can be used as a molecular marker for clinical diagnosis and treatment.

Key words: Prostate cancer, PBK, Biochemical recurrence

陈佳鸿, 方树敏, 梁应科, 刘泽贞, 朱学进, 蔡周达, 董卫民, 钟惟德. PBK在前列腺癌组织中的表达及临床意义[J]. 广州医药, 2017, 48(4): 1-6.

CHEN Jiahong, FANG Shumin, LIANG Yingke, LIU Zezhen, ZHU Xuejin, CAI Zhouda, DONG Weimin, ZHONG Weide. Expression and clinical significance of PBK in prostate cancer tissues[J]. Guangzhou Medical Journal, 2017, 48(4): 1-6.

参考文献

[1] SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics,2013[J]. Ca Cancer J Clin,2013,63 (1):11-30.
[2] ABE Y, MATSUMOTO S, KITO K, et al. Cloning and expression of a novel MAPKK-like protein kinase, lymphokineactivated killer t-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells[J]. J Biol Chem,2000,275 (28):21525-21531.
[3] GAUDET S, BRANTON D, LUE R A. Characterization of PDZ-binding kinase, a mitotic kinase[J]. Proc Natl Acad Sci,2000,97 (10) :5167-5172.
[4] ZHU F, ZYKOVA T A, KANG B S, et al. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells[J]. Gastroenterology,2007,133 (1) 219-231.
[5] SIMONS-EVELYN M,BAILEY-DELL K,TORETSKY J A, et al. PBK/TOPK Is a novel mitotic kinase which is upregulated in burkitt's lymphoma and other highly proliferative malignant cells[J]. Blood Cells Mol Dis,2001,27(5): 825-829.
[6] NANDI A, TIDWELL M, J KARP, et al. Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells[J]. Blood Cells Mol Dis,2004,32(1): 240-245.
[7] PARK J H, LIN M L, NISHIDATE T, et al. PDZ-binding kinase/T-LAK cell originated protein kinase, a putative cancer/testisantigen with an oncogenic activity in breast cancer[J]. Cancer Res, 2006,66(18): 9186-9195.
[8] ZYKOVA T A, ZHU F, LU C, et al. Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells[J]. Clin Cancer Res,2007,12(23): 6884-6893.
[9] NANDI A K, RAPOPORT A P. Expression of PDZ-binding kinase (PBK) is regulated by cell cycles pecific transcription factors E2F and CREB/ATF[J]. Leuk Res,2006,30(4): 437-447.
[10] PSTEIN J I, ALLSBROOK W C, JR.AMIN M B, et al. The 2005 International society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma[J]. Am J Surg Pathol,2005,40(2):1228-1242.
[11] MATSUMOTO S, ABE Y, FUJIBUCHI T, et al. Characterization of a MAPKK-like protein kinase TOPK[J]. Biophys Res Commun,2004,325(3):997-1004.
[12] ISHIDA S, HUANG E, ZU Z H, et al. Role for E2F in control ofboth DNA replication and mitotic functions as revealed from DNA microarray analysis[J]. Mol Cell Biol,2001,21(14):4684-4699.
[13] LENGAUER C, KINZLER K W, VOGELSTEIN B. Genetic instability in colorectal cancers[J]. Nature,1997,386(6625):623-627.
[14] FUJIBUCHI T, ABE Y, TAKEUCHI T, et al. Expression and phosphorylation of TOPK during spermatogenesis[J]. Dev Growth Differ,2006, 47(9):637-644.

PBK在前列腺癌组织中的表达及临床意义

Expression and clinical significance of PBK in prostate cancer tissues

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	张林洋, 朱玲玲, 朱国华. 中医药治疗前列腺癌研究进展[J]. 广州医药, 2021, 52(5): 135-138.
[2]	岑昕贝, 凌济忠, 万跃平, 万颂, 华伟, 江敏耀, 习明. NR3C1表达与前列腺癌生化复发的相关性研究[J]. 广州医药, 2020, 51(4): 22-27.
[3]	曾维威, 谢克基, 韦兴华, 莫灿程, 汤平. 17年间前列腺癌的临床特征变化[J]. 广州医药, 2018, 49(3): 5-9.
[4]	缪智雄, 朱旭生. ⁹⁹锝-亚甲基二膦酸盐治疗前列腺癌骨转移疗效观察[J]. 广州医药, 2018, 49(3): 94-96.
[5]	钟思苗, 陈瑞芳, 苏建平, 邹绮嫦, 吴小文. 不同分化程度前列腺癌经直肠超声图像特征观察[J]. 广州医药, 2018, 49(3): 103-105.
[6]	赵海波, 吴永定, 曾彦茹, 杨盛帮, 李博伟, 梁宇翔. NEK2与前列腺癌预后的相关研究[J]. 广州医药, 2017, 48(2): 1-5.
[7]	黎辉欣, 张海滨, 徐文峰, 刘建华. 腹腔镜前列腺癌根治术后尿失禁与否的尿动力学对比研究[J]. 广州医药, 2016, 47(6): 22-25.
[8]	毕学成, 刘久敏, 冯自卫, 吴永定. miR-221在前列腺癌细胞中的表达及对增殖的影响[J]. 广州医药, 2016, 47(5): 1-3.